Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. Material and Methods
Clinical data were collected from the FDA databases, RedBook online, National Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost information was extracted from the Redbook and published studies. The cost-effective analysis was performed using TreeAge Pro (Healthcare Version) version 2021. Results
The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity
","abstract_html":"<p>Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives</p> <p>The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. Material and Methods</p> <p>Clinical data were collected from the FDA databases, RedBook online, National Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost information was extracted from the Redbook and published studies. The cost-effective analysis was performed using TreeAge Pro (Healthcare Version) version 2021. Results</p> <p>The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity</p>","abstract_has_math":true,"creators":["Lotfi, Kamron"],"institution":null,"degree_name":"Master of Science (MS)","degree_level":"Thesis","degree_discipline":"Pharmaceutical Sciences","degree_department":null,"school":null,"contributors":["Enrique Seoane-Vazquez","Rosa Rodriguez-Monguio","Lawrence M. Brown"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2021,"date_issued":"2021-08-01T07:00:00Z","date_published":"2021-08-01T07:00:00Z","updated_at":"2026-07-24T01:38:16Z","subjects":["cost-effectiveness","gene therapy","LY","ICER","IC","Health Services Research","Other Pharmacy and Pharmaceutical Sciences","Patient Safety","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.chapman.edu/pharmaceutical_sciences_theses/18","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Enrique Seoane-Vazquez","Rosa Rodriguez-Monguio","Lawrence M. Brown"]},{"key":"dc:creator","label":"Author","values":["Lotfi, Kamron"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmaceutical Sciences"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Thesis"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science (MS)"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["cost-effectiveness","gene therapy","LY","ICER","IC","Health Services Research","Other Pharmacy and Pharmaceutical Sciences","Patient Safety","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_theses/18"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. Material and Methods
Clinical data were collected from the FDA databases, RedBook online, National Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost information was extracted from the Redbook and published studies. The cost-effective analysis was performed using TreeAge Pro (Healthcare Version) version 2021. Results
The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity
"]},{"key":"dc:source","label":"Dc Source","values":["Lotfi, K. Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia. [master’s thesis]. Irvine, CA: Chapman University; 2021. https://doi.org/ 10.36837/chapman.000294"]},{"key":"dc:title","label":"Title","values":["Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia"]}]}],"canonical_facts":{"dc:contributor":["Enrique Seoane-Vazquez","Rosa Rodriguez-Monguio","Lawrence M. Brown"],"dc:creator":["Lotfi, Kamron"],"dc:description.abstract":["Acute lymphoblastic leukemia (ALL) is a common type of adolescent and young adult leukemia in the United States (U.S.). Patients who are refractory or relapsed after receiving two or more lines of systemic therapy have the option of taking tisagenlecleucel. Due to the high cost of this treatment, a cost-effectiveness analysis was performed to assess the treatments for tisagenlecleucel, clofarabine combination, and blinatumomab. Objectives
The objective of this study is to evaluate the cost-effectiveness of tisagenlecleucel; clofarabine, etoposide, cyclophosphamide; and blinatumomab for the treatment of relapse- refractory ALL for adolescents and young adults from the U.S. health care payer perspective. Material and Methods
Clinical data were collected from the FDA databases, RedBook online, National Institutes of Health (NIH) research database, PubMed database, and clinicaltrials.gov. The cost information was extracted from the Redbook and published studies. The cost-effective analysis was performed using TreeAge Pro (Healthcare Version) version 2021. Results
The incremental cost of tisagenlecleucel was $520,050 compared to blinatumomab. The base case showed tisagenlecleucel effectiveness was the highest at 19.284, and blinatumomab effectiveness was 12.580. Tisagenlecleucel had an ICER of $77,573. The probability sensitivity
"],"dc:identifier":["https://digitalcommons.chapman.edu/pharmaceutical_sciences_theses/18"],"dc:source":["Lotfi, K. Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia. [master’s thesis]. Irvine, CA: Chapman University; 2021. https://doi.org/ 10.36837/chapman.000294"],"dc:subject":["cost-effectiveness","gene therapy","LY","ICER","IC","Health Services Research","Other Pharmacy and Pharmaceutical Sciences","Patient Safety","Pharmacoeconomics and Pharmaceutical Economics","Pharmacy Administration, Policy and Regulation"],"dc:title":["Cost-Effectiveness Analysis of Tisagenlecleucel, Blinatumomab, and Clofarabine for Treatment of B-cell Precursor Acute Lymphoblastic Leukemia"],"thesis:degree_discipline":["Pharmaceutical Sciences"],"thesis:degree_level":["Thesis"],"thesis:degree_name":["Master of Science (MS)"]},"updated_at":"2026-07-24T01:38:16Z"}